Calcineurin inhibitors in kidney transplantation: Friend or foe?

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 6, 2011, Pages 610-615

  Casey, Michael Jin ^a   Meier Kriesche, Herwig Ulf ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

calcineurin inhibitors; kidney; nephrotoxicity; transplantation

Indexed keywords

ALEFACEPT; AZATHIOPRINE; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; SOTRASTAURIN; STEROID; TACROLIMUS; TASOCITINIB;

ACUTE GRAFT REJECTION; BONE MARROW SUPPRESSION; CHRONIC KIDNEY FAILURE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GRAFT SURVIVAL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; REVIEW; WOUND HEALING IMPAIRMENT;

CALCINEURIN; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; SIROLIMUS;

EID: 80054746860     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32834b4343     Document Type: Review

References (53)

1. Nankivell BJ, Burrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326-2333. (Pubitemid 37509740)
2. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378-383. (Pubitemid 38282293)
3. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11:450-462.
4. Lodhi SA, Meier-Kriesche HU. Kidney allograft survival: the long and short of it. Nephrol Dial Transplant 2011; 26:15-17.
5. Borel JF, Feurer C, Gubler HJ, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6:468-475.
6. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2:1323-1327. (Pubitemid 9078430)
7. Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2:1033-1036. (Pubitemid 10213970)
8. Starzl TE, Klintmalm GB, Weil R 3rd, et al. Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet 1981; 153:486-494. (Pubitemid 11007294)
9. Cyclosporin A as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors. Preliminary results of a European multicentre trial. Lancet 1982; 2:57-60.
10. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309:809-815.
11. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. N Engl J Med 1986; 314:1219-1225.
12. Sutherland DE, Strand M, Fryd DS, et al. Comparison of azathioprine-antilymphocyte globulin versus cyclosporine in renal transplantation. Am J Kidney Dis 1984; 3:456-461. (Pubitemid 14116502)
13. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940. (Pubitemid 37064766)
14. Webster AC, Lee VWS, Champan JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81:1234-1248.
15. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22:1-15. (Pubitemid 351149996)
16. Srinivas TR, Schold JD, Guerra G, et al. MMF/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7:586-594. (Pubitemid 46376441)
17. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562-2575. (Pubitemid 350294223)
18. Knight RJ, Kahan BD. The place of sirolimus in kidney transplantation: can we reduce calcineurin inhibitor renal toxicity? Kidney Int 2006; 70:994-999. (Pubitemid 44344067)
19. Guerra G, Srinivas TR, Meier-Kriesche HU. Calcineurin inhibitor-free immunosuppression in kidney transplantation. Transpl Int 2007; 20:813-827. (Pubitemid 47390195)
20. Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol 2008; 3 (Suppl 2):S101-S116; Review.
21. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72:777-786. (Pubitemid 32879845)
22. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005; 18:22-28. (Pubitemid 41742941)
23. Kahan BD, The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000; 356:194-202. (Pubitemid 30446974)
24. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71:271-280. (Pubitemid 32126112)
25. Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9:1115-1123.
26. Pearson TC, Mulgaonkar S, Patel A, et al. Efficacy and safety of MMF (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the Spare-the-Nephron (STN) trial. Am J Transplant 2008; 8 (Suppl 2):213.
27. Weir MR, Mulgaonkar S, Chan L, et al. MMF-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79:897-907.
28. Meier-Kriesche HU, Lodhi S. 30-year retrospective on organ transplant immunosuppression in the era of calcineurin inhibitors. http://www.medsca-pe. org/viewarticle/726494 [accessed 1 April 2011].
29. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16:3755-3762. (Pubitemid 46211299)
30. Kamar N, Frimat L, Blancho G, et al. Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency. Transpl Int 2007; 20:128-134. (Pubitemid 46121990)
31. Bumbea V, Kamar N, Ribes D, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20:2517-2523. (Pubitemid 41548881)
32. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87:233-242.
33. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with MMF, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7:560-570. (Pubitemid 46376436)
34. Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a MMF-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002; 74:1725-1734. (Pubitemid 36019327)
35. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a MMF-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. Transplantation 2005; 16:2234-2240. (Pubitemid 41716457)
36. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74:1070-1076. (Pubitemid 35216097)
37. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4:1776-1785. (Pubitemid 39434437)
38. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6:514-522. (Pubitemid 43382137)
39. Rostaing L, Kamar N. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 2010; 23:133-142.
40. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9:1876-1885.
41. Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008; 85:821-826. (Pubitemid 351440746)
42. Nashan B, Curtis J, Ponticelli C, et al. Haas T; 156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78:1332-1340. (Pubitemid 39507973)
43. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very low-exposure cyclosporine A in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009; 88:1194-1202.
44. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535-546.
45. Durrbach A, Pestana JM, Pearson T, et al. A Phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT Study). Am J Transplant 2010; 10:547-557.
46. Larsen CP, Grinyó J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90:1528-1535.
47. Larsen C, Grinyo J, Medina Pestana J, et al. 3-year safety profile of belatacept in kidney transplant recipients from the BENEFIT and BENEFIT-EXT Studies. 2011 American Transplant Congress. Philadelphia, USA. Abstract # 228. Am J Transplant 2011; 11 (Suppl 2):99-100.
48. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT: a phase III study of belatacept vs. cyclosporine in kidney transplant recipients. 2011 American Transplant Congress. Philadelphia, USA. Abstract #227. Am J Transplant 2011; 11 (Suppl 2):99.
49. Vincenti F, Silva HT, Busque S, et al. Efficacy and safety of CP-690 550-MPA combination regimens in de novo kidney transplant patients: 12-month final results of a phase 2b study. 2011 American Transplant Congress. Philadelphia, USA. Abstract #4. Am J Transplant 2011; 11 (Suppl 2):30.
50. Budde K, Sommerer C, Becker T, et al. Sotrastaurin, a novel small molecule inhibiting protein kinase C: first clinical results in renal-transplant recipients. Am J Transplant 2010; 10:571-581.
51. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant 2008; 8:1972-1981.
52. Friman S, Arns W, Nashan B, et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant 2011; 11:1444-1455.
53. Bromberg J, Cibrik D, Steinberg S, et al. A phase 2 study to assess the safety and efficacy of alefacept (ALEF) in de novo kidney transplant recipients. 2011 American Transplant Congress. Philadelphia, USA. Abstract #533. Am J Transplant 2011; 11 (Suppl 2):190.